FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis

  • Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1
  • Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1
  • Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1
  • People dia
/by